Abstract
Patient response to asthma therapy is consistently observed to be heterogeneous. Pharmacogenomics is the study of inherited differences in interindividual drug disposition and effects, with the goal of selecting the optimal drug therapy and dosage for each patient. This review will cover selected examples of gene polymorphisms that influence the outcome of asthma therapy, and whole-genome expression studies using microarray technology that have shown tremendous potential for benefiting asthma pharmacogenomics. The utility of the mouse as an experimental system for pharmacogenomic discovery will also be discussed in the context of asthma therapy.
Keywords: Asthma, pharmacogenomics
Current Pharmaceutical Design
Title: Pharmacogenomics of Asthma
Volume: 12 Issue: 25
Author(s): Andreas Pahl, Ewald Benediktus and Ligia Chialda
Affiliation:
Keywords: Asthma, pharmacogenomics
Abstract: Patient response to asthma therapy is consistently observed to be heterogeneous. Pharmacogenomics is the study of inherited differences in interindividual drug disposition and effects, with the goal of selecting the optimal drug therapy and dosage for each patient. This review will cover selected examples of gene polymorphisms that influence the outcome of asthma therapy, and whole-genome expression studies using microarray technology that have shown tremendous potential for benefiting asthma pharmacogenomics. The utility of the mouse as an experimental system for pharmacogenomic discovery will also be discussed in the context of asthma therapy.
Export Options
About this article
Cite this article as:
Pahl Andreas, Benediktus Ewald and Chialda Ligia, Pharmacogenomics of Asthma, Current Pharmaceutical Design 2006; 12 (25) . https://dx.doi.org/10.2174/138161206778194105
DOI https://dx.doi.org/10.2174/138161206778194105 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Potential of Targeting TREM-1 in Inflammatory Diseases and Cancer
Current Pharmaceutical Design Impact of New Technologies on Pharmacogenomics
Current Pharmacogenomics and Personalized Medicine Phytochemicals and Antioxidants: An Evaluation in Understanding the Human Lifeline
Current Nutrition & Food Science Solubility Enhancement and Delivery Systems of Curcumin a Herbal Medicine: A Review
Current Drug Delivery Novel Therapeutic Approaches in Limiting Oxidative Stress and Inflammation
Current Pharmaceutical Biotechnology Solid Phase Extraction Method for the Determination of Cobalt in Water Samples on Duolite XAD-761 Resin Using 4-(2-Pyridylazo) Resorcinol by FAAS
Current Analytical Chemistry Quinoxalinone as a Privileged Platform in Drug Development
Mini-Reviews in Medicinal Chemistry Biopharmaceutical Potential of Two Ramalina Lichens and their Metabolites
Current Pharmaceutical Biotechnology Serotonin Type-4 (5-HT4) Receptors as Therapeutic Targets: Past and Future Roles of 5-HT4 Receptor Agonists
Current Medicinal Chemistry - Central Nervous System Agents Drug Repurposing for the Treatment of Staphylococcal Infections
Current Pharmaceutical Design The Use of Nitric Oxide Synthase Inhibitors in Inflammatory Diseases: A Novel Class of Anti-Inflammatory Agents
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents IgE Binding Epitopes of Bla g 6 from German Cockroach
Protein & Peptide Letters Mechanism of Action of Methamphetamine within the Catecholamine and Serotonin Areas of the Central Nervous System
Current Drug Abuse Reviews Editorial [Hot Topic: Oxidative Balance: Experimental and Clinical Perspectives (Executive Editor: Fortunato Vesce)]
Current Pharmaceutical Design IgE-Binding Epitope Analysis of Bla g 5, the German Cockroach Allergen
Protein & Peptide Letters miRNAs in SARS-CoV 2: A Spoke in the Wheel of Pathogenesis
Current Pharmaceutical Design Modification Strategies of Lipid-Based Nanocarriers for Mucosal Drug Delivery
Current Pharmaceutical Design Xenobiotic and Non-Xenobiotic Interventions in the Microbiome Therapeutics
Current Drug Metabolism Proteases as Anti-Cancer Targets - Molecular and Biological Basis for Development of Inhibitor-Like Drugs Against Cancer
Anti-Cancer Agents in Medicinal Chemistry Antimicrobial Evaluation of Erythrinan Alkaloids from Erythrina cristagalli L.
Medicinal Chemistry